Results 31 to 40 of about 456 (124)

Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains. [PDF]

Antimicrob Agents Chemother
ABSTRACT This study comprehensively assessed the activity of manogepix (MNGX), ibrexafungerp (IBF), amphotericin B (AMB), rezafungin (RZF), and caspofungin (CAS) against planktonic cells and mature biofilms of Candida spp.—reference and clinical strains using the Calgary ...
Ceballos-Garzon A, Lebrat J, Holzapfel M, Josa DF, Welsch J, Mercer D.   +5 more
europepmc   +3 more sources

Clinical efficacy and safety of a novel antifungal, Fosmanogepix, in patients with candidemia caused by Candida auris : results from a Phase 2 trial [PDF]

, 2023
DATA AVAILABILITY: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified ...
Bien, Paul A., Boffard, Kenneth D., Hodges, Michael R., Oborska, Iwona, Ople, Eric, Pappas, Peter G., Paruk, Fathima, Tawadrous, Margaret, Vazquez, Jose A., Wedel, Pamela   +9 more
core   +1 more source

Mutations in transcription factors that confer fluconazole resistance also confer reduced susceptibility to manogepix in Candida auris (Candidozyma auris), Candida albicans, Candida parapsilosis, and Candida glabrata (Nakaseomyces glabratus). [PDF]

Antimicrob Agents Chemother
ABSTRACT The fungal pathogen Candida auris is of global concern due to high levels of multidrug resistance and its propensity to cause infectious outbreaks. Over 90% of isolates are resistant to fluconazole, the most commonly prescribed antifungal worldwide.
Barker KS, Patterson HP, Morschhäuser J, Cuomo CA, Wiederhold NP, Rogers PD.   +5 more
europepmc   +3 more sources

The Neosartorya fischeri Antifungal Protein 2 (NFAP2) [PDF]

, 2021
Candida auris is a potential multidrug-resistant pathogen able to persist on indwelling devices as a biofilm, which serve as a source of catheter-associated infections.
Andrew M. Borman, Fruzsina Nagy, Györgyi Váradi, Gábor K. Tóth, Karina Vadászi, Lajos Forgács, Liliána Tóth, László Galgóczy, László Majoros, Renátó Kovács, Zoltán Tóth   +10 more
core   +1 more source

1260. Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018-2019) Stratified by Infection Type [PDF]

Open Forum Infectious Diseases, 2020
Abstract Background Existing antifungal agents are active against many common fungal pathogens; however, breakthrough fungal infections occur and often involve less frequently encountered yeast and mould isolates.
Huband, Michael D, Pfaller, Michael A, Flamm, Robert K, Messer, Shawn A, Schaefer, Beth A, Bien, Paul, Castanheira, Mariana   +6 more
openaire   +1 more source

Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs

Antimicrobial Agents and Chemotherapy, 2020
Fosmanogepix is a novel prodrug in a new class of antifungal agents. Manogepix is the active moiety. We evaluated the CLSI and EUCAST MICs of manogepix and eight comparators against Candida auris . CLSI M27-A3 susceptibility testing of manogepix was performed for 122 C.
Maiken Cavling Arendrup, Anuradha Chowdhary, Karin Meinike Jørgensen, Joseph Meletiadis   +3 more
openaire   +5 more sources

<i>In vitro</i> activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022). [PDF]

Antimicrob Agents Chemother
ABSTRACT Manogepix is a potent new antifungal agent targeting the fungal Gwt1 enzyme. Manogepix has previously demonstrated potent in vitro activity against clinical isolates of both Candida (except Candida krusei ) and Aspergillus ...
Pfaller M, Huband M, Bien PA, Carvalhaes CG, Klauer A, Castanheira M.   +5 more
europepmc   +3 more sources

Antagonism of the Azoles to Olorofim and Cross-Resistance Are Governed by Linked Transcriptional Networks in Aspergillus fumigatus [PDF]

, 2022
Aspergillosis, in its various manifestations, is a major cause of morbidity and mortality. Very few classes of antifungal drugs have been approved for clinical use to treat these diseases and resistance to the first-line therapeutic class, the triazoles ...
Amich, Jorge, Bin Shuraym, Hajer, Bromley, Michael J, Goldman, Gustavo H, Gsaller, Fabio, Hemmings, Sam, Storer, Isabelle S R, Valero, Clara, van Rhijn, Norman   +8 more
core   +3 more sources

1275. Evaluation of in vitro activity of manogepix against multidrug-resistant and pan-resistant Candida auris from the New York Outbreak [PDF]

Open Forum Infectious Diseases, 2020
Abstract Background An ongoing Candida auris outbreak in the New York metropolitan area is the largest recorded to date in North America. NY C. auris isolates demonstrate resistance to fluconazole and variable resistance to other antifungals.
Zhu, Yan Chun, Kilburn, Shannon N, Kapoor, Mili, Chaturvedi, Sudha, Shaw, Karen J, Chaturvedi, Vishnu   +5 more
openaire   +1 more source

2043. In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020-2021) Stratified by Infection Type

Open Forum Infectious Diseases, 2022
Abstract Background Manogepix is a new antifungal with a novel mechanism of action and potent in vitro activity against Candida (except C. krusei), Aspergillus, and rare mold isolates. The manogepix prodrug fosmanogepix is in Phase 2 development for the treatment of invasive mold infections caused by ...
Huband, Michael D, Pfaller, Michael, Carvalhaes, Cecilia G, Bien, Paul, Castanheira, Mariana   +4 more
openaire   +1 more source